LONDON, Oct. 30 /PRNewswire/ -- Chiltern, a leading global clinical research organization (CRO), today announced the acquisition of Clinical Trial Management Services, Inc. (CTMS) a Bristol, Tennessee based CRO offering high quality services throughout the United States. From February 2008 the combined operation will be known exclusively as 'Chiltern'.
Established in 1989 by Dr. Robert Vann, John Vann and Ben Essary, CTMS has extensive experience conducting clinical trials in a wide variety of therapeutic areas with an emphasis on respiratory, gastrointestinal, central nervous system, infectious disease and ophthalmology indications. The company employs 190 people located in offices in Bristol and Winston-Salem, NC. John Vann, previously President and CEO of CTMS, today assumes overall leadership of Chiltern's U.S. operations, becoming Executive Vice-President Americas. Dr Robert Vann retires after a long and successful career in clinical research.
"We are looking forward to bringing together the complementary strengths and resources of Chiltern and CTMS," said Glenn Kerkhof, Chiltern's Chief Executive Officer. "The acquisition of CTMS significantly increases our presence and expertise within the US and strengthens Chiltern's position as a global CRO. CTMS and Chiltern have compatible cultures and are equally focused on delivering high quality services to the pharmaceutical, device and biotech industries. Detailed planning for the integration of our operations is underway and we are very confident of a smooth transition for customers, suppliers and employees alike."
"We are delighted to have found in Chiltern a buyer that not only
shares our commitment to excellence in clinical research and service
delivery to clients, but also provides our employees with opportunities for
growth and participation internationally," said John Vann. "We have been
struck throughout by the compatible nature of our organizations and the
essentially seamless way w
Copyright©2007 PR Newswire.
All rights reserved